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Purpose or Objective: The radiation therapy of head and 
neck tumors is burdened by high toxicity to organs at risk 
(OARs) with consequent administered dose limitations to the 
target and compromised clinical outcome. We investigated 
the contribution of functional/biological imaging obtained by 
Positron Emission Tomography (PET/CT) in Gross Tumor 
Volume (GTV) and Clinical Target Volume (CTV) definition of 
primary tumor and regional lymph nodes in head and neck 
cancer, for a more accurate target delimitation resulting in 
lower toxicity to OARs. 
 
Material and Methods: From March 2103 to June 2014 we 
examined 51 patients with head and neck cancer and defined 
clinical volumes with the aid of only morphological CT images 
and with the aid of diagnostic PET/CT images. Then we 
evaluated, through tests of statistical significance, the 
overlap of GTV and CTV obtained with each of the two 
methods respectively. Moreover usefulness of PET/CT in 
preventing geographic errors for a more accurate target 
definition, resulting in peritumoral tissues preservation and 
less toxicity to the OARs, was evaluated as well. The 
influence of two different imaging techniques in TNM staging, 
which is important for treatment planning, was investigated. 
 
Results: In 33 of 51 patients the TNM staging obtained by 
PET/CT was similar to that performed by CT images, but in 
39% of the cases the primary tumor GTV defined by PET/CT 
was significantly smaller and restricted compared to that 
defined by CT only (p <0.016). Due to the better GTV 
definition in terms of size and location, the OARs are 
potentially better preserved. In 12 patients the more 
accurate definition of tumor margins made possible by 
PET/CT produced a different T than that obtained with CT 
evaluation only; in 6 patients PET/CT identified metastases 
to regional lymph nodes not assessed with CT images only. It 
was not observed significant variation of the nodal volumes. 
 
Conclusion: The use of PET/CT imaging allows the realization 
of more precise target volume and better defined clinical 
volumes, with a possible better preservation of the OARs and 
lower toxicity. Functional imaging PET/CT helps the radiation 
oncologist not only in the process of treatment planning, but 
has the advantage of identify treatable disease not 
highlighted on morphological CT images. It is therefore 
recommended to use a PET/CT scan in the radiotherapy 
planning process in order to achieve a more appropriate 
treatment planning in head and neck tumors. 
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Purpose or Objective: Concomitant radiotherapy + 
cetuximab association has shown superiority to exclusive 
radiotherapy for locally advanced head and neck cancers 
(LAHNC). Data on this association are scarce for the elderly 
despite its rising incidence. Initial clinical trials that led to its 
approval have not included patients>70 years. The objective 
of this study was to assess efficacy and toxicity of 
concomitant radiotherapy and cetuximab for patients 
aged>70 years with LAHNC 
 
Material and Methods: A retrospective monocentric data 
collection was performed in the Antoine Lacassagne center, 
France. Inclusion criterias were: age>70 years at time of 
diagnosis, histologically proven LAHNC, treated with 
radiotherapy combined with cetuximab. Non-inclusion 
criterias were: previous radiotherapy and metastases at time 
of diagnosis 
 
Results: Thirty-five patients were included between 2008 and 
2012. Median follow up was 22 months. Median age was 74 
years (70-86). Median performance status was 1(0-2). 
Female/male sex ratio was 0.34. Tumor sites were: 
Oropharynx(57.1%), larynx(20%), hypopharynx(14.3%), oral 
cavity(2.9%), rhinopharynx(2.9%), lymph node with unknown 
primary(2.9%). Using TNM classification, tumors were: 
T1(5.9%), T2(35.3%), T3(35.3%), T4(22.9%), N0(28.6%), 
N1(8.6%), N2(48.6%), N3(14.3%). Median radiotherapy dose 
was 70 Gy(60-70). 40% of patients were treated with 
intensity-modulated radiotherapy, the rest were treated with 
conventional 3D radiotherapy. 94.3% of patients paused 
radiotherapy due to toxicity. 29% had a cetuximab dose-
reduction and 1 patient had a definitive interruption. Median 
survivals were respectively: 49 months for overall 
survival(Standard-Error (SE)=8) and 32 months for relapse 
free survival(SE=10). Two-year local-regional relapse and 
metastatic relapse free survivals were respectively 
59%(SE=10) and 74%(SE=10). Median body mass index (BMI) 
was 24.6(17.3–38) before treatment and 23, 24 after 
treatment(16.3–34.7). Median weight variation was 4 
kilograms(-16 to +6). Ninety-four percent of patients had 
nutritional support: 37.8% had oral nutritional supplements 
only, 56.8% had enteral nutrition and 2.7% parenteral 
nutrition. Skin reaction and mucositis were the major 
toxicities recorded. Toxicities details are reported in table 1 
 
 
Conclusion: Concomitant radiotherapy and cetuximab seems 
to be an effective therapy in the elderly population with 
encouraging results similar to the literature concerning its 
efficacy and toxicity. This treatment should be considered 
for patients > 70 years. 
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Purpose or Objective: In an era of personalized treatment 
there is a great interest in identifying factors which might 
help to predict patient response to RT. EGFR role in this 
S522                                                                                                                                                  ESTRO 35 2016 
_____________________________________________________________________________________________________ 
setting remains still controversial, despite the large 
consensus as a promising candidate to become a biomarker 
that could further improve application and efficacy of 
radiation therapy (RT) in head and neck squamous cell 
carcinoma (HNSCC). Moreover, most of the studies refer to 
series of patients who underwent RT alone or in combination 
with Cetuximab. We performed a retrospective analysis on 
the prognostic value of EGFR expression in HNSCC treated 
with surgery and postoperative RT.  
 
Material and Methods: We analyzed 69 patients with an 
histological diagnosis of HNSCC who underwent adjuvant RT 
after surgery in our Institute from 1997 to 2003. A 3D 
conformal RT was delivered with a 6MV accelerator using a 
conventional fractionation (median 60 Gy, range 34.2-70 Gy) 
Median follow-up was 3.73 years (range 0.17-12.25 ys). None 
of these patients were treated with postoperative 
concomitant chemotherapy. Tumor samples used for the 
determination of EGFR were obtained from surgical 
specimens. Membrane features (intensity, extension, 
distribution) and percentage of EGFR expression were 
evaluated and a statistical analysis (univariate) was 
conducted to correlate these parameters with Overall 
Survival (OS) and Disease Free survival (DFS).  
 
Results: EGFR was overexpressed in 45,5% of our patients 
(median value used as threshold). No significant correlation 
(p value= 0.90) has been found between patients with an 
overexpression of EGFR and OS or DFS. Among patients with 
laryngeal carcinoma, those with overexpressed EGFR have 
showed a lower OS (not statistically significant) and DFS 
(p=0.05). Considering separately the membrane features, the 
intensity of the EGFR staining has been found statistically 
correlated with both OS (p= 0.03) and DSF (p=0.001). 
Moreover, a stratification of patients was performed 
combining extension and intensity of EGFR immunolabelling 
in tumour cell membranes, and their distribution following a 
three-point score: patients with 3+ score (intense and 
complete labelling and patchy distribution) presented the 
lowest OS and DFS and the difference was highly significant 
for both OS and DFS (p= < 0.0001). The same result was 
observed in the subgroup of patients with a diagnosis of 
larynx carcinoma.  
 
Conclusion: Based on our results it is still reasonable that the 
analysis of EGFR expression, especially referring to 
membrane features, might be a prognostic value for OS and 
DFS in locally advanced HNSCC treated with adjuvant RT. A 
clinical validation in prospective trials of the suggested 
three-point score system could be useful to select patients 
with worse prognosis that might benefit from more aggressive 
treatments.  
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Purpose or Objective: Tumor hypoxia is a common feature of 
locally advanced head and neck cancer (HNSCC) that is 
associated with higher malignancy and increased 
radioresistance. Tumor-to-blood ratios ≥1.2 are generally 
thought to indicate hypoxia. Nevertheless, previous studies 
use various thresholds to define tumor hypoxia. The following 
analysis tries to elucidate which threshold may be the most 
appropriate to determine hypoxic volume in respect to 
treatment success. 
 
Material and Methods: A prospective study was performed to 
determine changes in tumor hypoxia during primary 
chemoradiation (pRCTx) of HNSCC at our institution. Tumor 
hypoxia was non-invasively assessed by [18F]-Fluoro-
Misonidazole (F-MISO) PET/CT 2.5 h p.i. at baseline (week 0) 
and in week 2 and 5 of treatment, respectively. Hypoxic 
volumes (HV) were generated using thresholding at different 
levels of 1.2, 1.3, 1.4, 1.5 multiplied with the background-
uptake, which was defined as SUVmean within the ipsilateral 
trapezium muscle, as advised by a nuclear-medicine 
specialist. ∆-values of decrease of HV (∆HV) during treatment 
were obtained in weeks 0, 2 and 5 and correlated with local 
failure. As four patients showed local failure (LF), two groups 
of four patients each were made: four showing LF, four 
patients showing complete remission (CR). Before t-test 
analysis normal sample distribution was confirmes with 
Shapiro–Wilk test. Significance-level was defined as p<0.005. 
 
Results: We analysed 4 patients without local failure in 
comparison to 4 patients with LF to show differences of ∆ -
values in weeks 0 to 2, 2 to 5 and 0 to 5 of the HV. All 
patients primarily treated for HNSCC with dRCTx were 
included. Each patient received a total dose of 70Gy in 35 
fractions. Concomitant cisplatin chemotherapy was 
administered in weeks 1, 4 and 7. The mean follow-up time 
was 16.9 months (range: 10-22 months). Mean time to LF was 
9.5 months (range: 6-15 months). For patients in CR all ∆ -HV 
(mean) show proportional decrease in weeks 0 to 5. This is 
true for every threshold factor from 1.2 to 1.5. In those 
patients showing LF, ∆ -HV (mean) demonstrates not only a 
decrease in HV but also some increase at each of the time 
increments. There is a general decrease (p=0.0073) between 
week 0 and 5, while between week 0 and 2 and 2 and 5, a 
rise in ∆ -HV(mean) can be shown (p=0.2339, p=0.0649, 
respectively). 
 
 
 
Conclusion: A decrease in ∆ -HV (mean) was shown at any 
time point, for any factor the tumor-to-background-ratio was 
multiplied with, in patients with CR. In patients with LF, the 
hypoxic volume showed inconsistence over time, at least at 
one time of measurement there was an increase in hypoxic 
volume. The choice of the threshold for determination of 
hypoxic volume in FMISO-PET/CT remains a crucial question 
that could not be answered at this point. To elucidate this 
larger patient numbers are needed. 
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